Skip to main content

Depression clinical trials at UCSF
10 in progress, 4 open to new patients

  • Cellular Aging and Neurobiology of Depression Study

    open to eligible people ages 21–60

    We are conducting an eight week longitudinal study to learn if blood levels of certain naturally occurring compounds and genetic markers differ between patients with depression and healthy adults who are not depressed, and if any such differences relate to memory performance, mood, and neurobiology. We will do this by comparing the unmedicated depressed patients with matched healthy controls at baseline and then following the depressed patients over the course of eight weeks of standardized antidepressant treatment to gauge which baseline abnormalities normalize over the course of treatment.

    San Francisco, California

  • Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project

    open to eligible people ages 65 years and up

    The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD). This is a non-randomized, observational, non-treatment study. One hundred and twenty (120) subjects who meet criteria for Major Depression or LLD will be enrolled for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison. Depression history, symptom severity and health information will be collected at the initial psychiatric visit to determine eligibility. A 3 Tesla (3T) Magnetic resonance imaging (MRI) scan and florbetapir (18F-AV-45) amyloid imaging will be conducted at the ADNI clinic site visits. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.

    San Francisco, California and other locations

  • Group Therapy for Depressed Dementia Caregivers

    open to eligible people ages 45 years and up

    Depression in family caregivers of relatives with Alzheimer's Disorder and related dementias is a serious public health problem. This is a randomized, controlled, single-blind pilot clinical trial of 50 depressed caregivers, to determine the efficacy and mechanisms of group therapy for depressed dementia caregivers.

    San Francisco, California

  • Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

    open to eligible males ages 50 years and up

    The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).

    San Francisco, California

  • ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes

    Sorry, currently not accepting new patients, but might later

    This study will be conducted to determine the pharmacodynamics, cardiovascular and biochemical effects of succinylcholine when given during electroconvulsive therapy. (ECT). This is a single center, prospective, study in patients who will be receiving ECT as indicated and prescribed by their psychiatrist. The study will be performed twice on each patient, 48-72 hours apart during consecutively scheduled ECT procedures.

    San Francisco, California

  • Evaluating the Feasibility of Disseminating a Novel Mobile Platform to Treat Depression

    Sorry, not yet accepting patients

    The goal of this project is to conduct a pilot study to test the utility of a Natural Language Processing (NLP) clinical messaging tool to improve the reach and the quality (fidelity and competency) of coaches providing behavioral activation (BA) strategies through a mobile mental health app called Personalized Real-time Intervention for Motivational Enhancement (PRIME). This study will improve the reach of clinicians by using a NLP-powered messaging tool, which will ensure fidelity to the BA model and clinicians will have access to real-time clinical information about their patients to guide more targeted treatment (competence). If successful, PRIME could operate as a cost effective tool for clinicians to extend their reach and an accessible treatment for the population of those struggling with depression.

    San Francisco, California

  • Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression

    Sorry, not yet accepting patients

    The specific focus of this study is to gather data regarding the effects of a psychological therapy known as Problem Solving Therapy (PST) on cerebral blood flow (CBF), cortical gray matter (GM) atrophy, subcortical white matter (WM) lesion burden, and measures of cognitive function in subjects with Late Life Major Depressive Disorder (LLD). This research goal will be achieved by recruiting 110 individuals over the age of 65 with LLD. The primary outcomes will be change in CBF, change in GM atrophy, change in WM lesion, change in cognitive function, and change in depression severity from baseline to the end of 12 weeks of PST.

    San Francisco, California

  • PRIME Care (PRecision Medicine In MEntal Health Care)

    Sorry, not yet accepting patients

    The focus of this application is on the impact of providing depressed Veterans and their providers with the results of pharmacogenetic (PGx) testing for psychotropic medications. The project focuses on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat Major Depressive Disorder (MDD) and whether use of the test results improves patient outcomes. MDD is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of functional impairment and mortality. Validation of a PGx test to personalize the treatment of MDD represents an important opportunity to improve the healthcare of Veterans.

    San Francisco, California and other locations

  • Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care

    Sorry, not yet accepting patients

    Substance use disorders (SUDs) and depression in HIV-infected patients result in poor HIV outcomes, yet are often unrecognized and untreated. To address these problems, this study examines the implementation and effectiveness of a clinical intervention consisting of self-administered tablet-based SUD and depression screening at routine HIV primary care clinic visits, followed by evidence-based treatments for SUD and depression delivered by a behavioral health specialist. If successful, this study has potential to reduce SUD- and depression-related problems and reduce HIV treatment disparities for patients with these comorbidities.

    Oakland, California

  • Pediatric Open-Label Extension Study

    Sorry, in progress, not accepting new patients

    This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326

    San Francisco, California and other locations